Atopic Dermatitis is Gaining Traction as Prevalence of Food Allergies Increases
The rising prevalence of allergic responses, which play a crucial part in food allergies, is propelling the industry forward. Food Allergy Research and Education (FARA) estimates that 32 million Americans have food allergies, including 5.6 million children under the age of 18. Approximately 40% of children having food allergies are allergic to multiple foods. Furthermore, according to a report from the Australian Society of Clinical Immunology and Allergy (ASCIA) in May 2023, food allergy affects around 12% of infants, 6-9% of children, and 4% of adults in Australia and New Zealand. Similarly, according to the NCBI article, infants with temporary skin barrier disruption and chronic atopic dermatitis are more likely to develop food allergies. In an oral food challenge, one-third of the patients had serious cases of atopic dermatitis with positive symptoms. According to the same study, several kids with atopic dermatitis had asymptomatic food sensitivity. As food allergies cause atopic dermatitis, an increasing global incidence of allergic responses is expected to raise demand for treating atopic dermatitis, accelerating market expansion.
Furthermore, the advent of biologic treatments such as dupilumab signifies a revolutionary progress in treating moderate to severe atopic dermatitis. Biologics differ from traditional treatments by aiming at specific inflammatory pathways related to the disease's development, resulting in better symptom management and decreased reliance on systemic corticosteroids and their side effects. Patients who received dupilumab have experienced marked enhancements in itch intensity, skin sores, and overall quality of life, highlighting its importance in revolutionizing treatment approaches and providing optimism for individuals who did not respond well to traditional treatments before.
Furthermore, the advent of biologic treatments such as dupilumab signifies a revolutionary progress in treating moderate to severe atopic dermatitis. Biologics differ from traditional treatments by aiming at specific inflammatory pathways related to the disease's development, resulting in better symptom management and decreased reliance on systemic corticosteroids and their side effects. Patients who received dupilumab have experienced marked enhancements in itch intensity, skin sores, and overall quality of life, highlighting its importance in revolutionizing treatment approaches and providing optimism for individuals who did not respond well to traditional treatments before.
Topical Innovations & Growing Awareness of Atopic Dermatitis Propels Market Expansion
Medical institutions educate people about atopic dermatitis disease and its primary treatment at home. The World Health Organisation reports that skin conditions impact almost 900 million individuals worldwide on a continuous basis, making them one of the most common diseases affecting human health. For instance, World Atopic Eczema Day is celebrating as a result of a collaboration between the International Coalition of Dermatology Patient Organisations (Global Skin) and the European Federation of Allergy and Airways Diseases Patient Associations (EFA) to increase awareness of the condition both globally and in Europe. The introduction of biologics and small molecules, premium-priced drugs that replace generic first-line and second-line therapies, and enhanced diagnostics are propelling the global atopic dermatitis market forward.
Progress in topical treatments for atopic dermatitis is centred on creating new formulations and delivery methods to tackle major challenges. Sophisticated formulations target improving drug penetration, maximizing effectiveness against inflammation and itching, and reducing negative side effects such as skin irritation. Innovative methods of drug delivery, such as nanoparticles and micelles, provide controlled release functions that extend the effectiveness of treatment and decrease the need for frequent administration, ultimately enhancing patient adherence. These advances are a hopeful new area in dermatological treatment, aiming to provide safer, more efficient options that address the various requirements of patients with atopic dermatitis.
Progress in topical treatments for atopic dermatitis is centred on creating new formulations and delivery methods to tackle major challenges. Sophisticated formulations target improving drug penetration, maximizing effectiveness against inflammation and itching, and reducing negative side effects such as skin irritation. Innovative methods of drug delivery, such as nanoparticles and micelles, provide controlled release functions that extend the effectiveness of treatment and decrease the need for frequent administration, ultimately enhancing patient adherence. These advances are a hopeful new area in dermatological treatment, aiming to provide safer, more efficient options that address the various requirements of patients with atopic dermatitis.
Recent Trends in Atopic Dermatitis Market
- The approval and adoption of biologics such as dupilumab highlight a shift towards targeted therapies.
- Ongoing innovation in topical treatments, including new formulations and delivery systems aimed at enhancing drug efficacy and improving patient adherence.
- Increasing use of biomarkers and genetic profiling enables personalized treatment strategies, optimizing therapy selection.
- Growing emphasis on developing and evaluating treatments specifically tailored to paediatric populations.
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
High Cost of Atopic Dermatitis Treatment May Limit Market Expansion
The primary issue limiting market expansion is the high cost of atopic dermatitis treatment. Furthermore, due to severe atopic disorders, drugs and therapy for atopic dermatitis can be highly expensive. Additionally, owing to corticosteroids have several negative effects, doctors seldom suggest them for the treatment of atopic dermatitis. Although oral corticosteroids are allowed for the treatment of atopic dermatitis, physicians do not prescribe them due to rebound. Dupixent can cause significant allergic reactions and eye issues such as pink eye (conjunctivitis) and corneal inflammation (keratitis). Cold sores in the mouth or on the lips, injection site responses, and eye and eyelid inflammatory conditions, including redness, swelling, and itching, are the most prevalent adverse effects.
Additionally, consistently applying topical treatments is essential for treating atopic dermatitis, but can be difficult, particularly for children and those with a large area of skin affected. Challenges such as the lengthy application process, the discomfort of applying medications to sensitive skin, and the importance of following treatment schedules can impede adherence. These obstacles could result in irregular utilization, impacting the effectiveness of treatment and prolonging the relief of symptoms. Dealing with these problems involves educating patients, using simpler application methods, and implementing supportive healthcare strategies to increase treatment adherence and enhance outcomes for all patient populations impacted by atopic dermatitis.
Additionally, consistently applying topical treatments is essential for treating atopic dermatitis, but can be difficult, particularly for children and those with a large area of skin affected. Challenges such as the lengthy application process, the discomfort of applying medications to sensitive skin, and the importance of following treatment schedules can impede adherence. These obstacles could result in irregular utilization, impacting the effectiveness of treatment and prolonging the relief of symptoms. Dealing with these problems involves educating patients, using simpler application methods, and implementing supportive healthcare strategies to increase treatment adherence and enhance outcomes for all patient populations impacted by atopic dermatitis.
Product Innovation by Prominent key Players Accountable for Market Growth
Advancements and novel innovations in the atopic dermatitis market are necessary to broaden treatment choices at different levels of severity, boost safety profiles, tailor therapies, enhance topical formulations for increased compliance, and incorporate digital tools for patient care and education, ultimately enhancing results and patient well-being. For instance, in July, 2024, FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% by Arcutis Biotherapeutics, Inc for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age. In addition, in May 2023, AbbVie announced that the FDA has approved RINVOQ (upadacitinib) for the medical treatment of individuals with moderately to very active Crohn's disease who had an inadequate response.
Know Your Competitors and Strengthen Market Share Effectively
Rising Prevalence of Atopic Dermatitis Fuels the Expansion of The North American Market
The United States is anticipated to have a sizable market share in North America. According to a paper published in the Journal of the American Medical Association (JAMA), approximately 45% of survey participants had moderate atopic dermatitis in 2021, while 28% had severe atopic dermatitis. Furthermore, improved reimbursement regulations, increased business interactions between pharmaceutical firms and contract research organisations in emerging regions, and product developments are propelling the industry forward. For instance, Evelo Biosciences, Inc. announced in February 2022 that the first patient in EDP1815-207, its Phase 2 randomised clinical research of EDP1815 for the treatment of people with severe, moderate, and mild atopic dermatitis. Furthermore, increased investments in atopic dermatitis are likely contributing to the region's growth. According to a National Institutes of Health (NIH) article released in March 2023, the estimated budget for atopic dermatitis research in 2022 was US$ 39 million and US$ 40 million in 2023. As a result, the market is projected to grow significantly throughout the forecast period.
Searching for a Country or Region-Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
The report provides a detailed overview of the atopic dermatitis market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for atopic dermatitis market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the atopic dermatitis market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the atopic dermatitis market. Some key country and region included in the atopic dermatitis market report as follows:
| Regions | Countries |
|---|---|
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Atopic Dermatitis Market Research Report Covers In-depth Analysis on:
- Atopic dermatitis market detailed segments and segment-wise market breakdown
- Atopic dermatitis market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in atopic dermatitis industry)
- Current, historical and forthcoming 10 years market valuation in terms of atopic dermatitis market size (US$ Mn), volume (Units), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Atopic dermatitis market demand analysis
- Atopic dermatitis market pricing analysis over forecast period (by key segment and by region)
- Atopic dermatitis market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in atopic dermatitis market
- Regulatory landscape by key regions and key countries
- Supply chain and value chain analysis in atopic dermatitis market
- Atopic dermatitis market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on atopic dermatitis market forecast by countries
- Mergers and acquisitions in atopic dermatitis market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What are the key trends in atopic dermatitis market?
Key trends include increased awareness about the condition, advancements in treatment options and a growing focus on personalized medicine and biologics.
What factors are driving the growth of atopic dermatitis market?
Major drivers include the increasing incidence of atopic dermatitis, rising healthcare expenditure and continuous advancements in treatment and diagnostic technologies.
What are the challenges faced by atopic dermatitis market?
Challenges include high treatment costs, limited access to advanced therapies in low-income regions and variability in patient response to treatments.
Which regions are expected to see significant growth in the atopic dermatitis market?
The market is anticipated to see substantial growth in North America and Europe due to rising prevalence rates and advancements in treatment options.
